Researchers Announce Blood Test to Assess Alzheimer’s Risk Before Symptoms

1-Minute Brief

Early detection through blood testing could enable interventions before Alzheimer’s symptoms develop, but further validation is required.

Key Facts

• Blood tests measuring p-tau217 levels are being studied for their ability to predict Alzheimer’s risk years before symptoms appear.
• An at-home finger prick test has been developed to help identify Alzheimer’s risk.
• Experts caution that more validation is needed before these blood tests are widely adopted.
• Researchers combined blood testing with computerised cognitive assessments to evaluate risk.
• The tests are not yet established as definitive diagnostic tools, according to experts.

What Happened

Scientists have introduced blood tests, including an at-home finger prick version, that may help predict a person’s risk of developing Alzheimer’s disease before symptoms manifest. These tests measure biomarkers such as p-tau217 and may be used alongside cognitive assessments.

Why It Matters

Early identification of Alzheimer’s risk could allow for earlier interventions and planning, potentially improving patient outcomes. However, experts emphasize that these tests require further validation before routine clinical use.

What's Next

Additional studies and validation are expected to determine the accuracy and reliability of these blood tests. Regulatory review and broader clinical trials may follow before widespread adoption.